Medicine
Doxycycline 200 mg delayed-release tablet
Doxycycline 200 mg delayed-release tablet is a generic prescription medicine for oral use, made by 5 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25° C (77° F), excursions permitted to 15° to 30° C (59° to 86° F).
Key facts
- Active ingredient (INN)
- Doxycycline
- Brand
- Sold under the generic name
- Strength
- 200 mg
- Dosage form
- Delayed-release tablet
- Route
- Oral
- Packs
- 30 tablets, 100 tablets, 60 tablets and 13 more
- Manufacturers
- Alembic PharmaceuticalsIndiaAvet PharmaceuticalsIndiaSolco HealthcareMayne Pharma CommercialActavis Pharma
- Origin register
- US FDA, United States
- Storage
- Store at 25° C (77° F), excursions permitted to 15° to 30° C (59° to 86° F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A01AB22 Doxycycline
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 February 2016
- Identifiers
- RxCUI 406524, 434018, 799048 +2DailyMed set ID 3ae4ca12-be39-46b9-bc4c-f8356776c175, 0a18d4c7-9484-4d3e-b61b-e81fe63fefec, cd2ab9b8-9619-4199-8a5d-83377b3274d1 +3NDC 62332-484, 43547-325, 68308-716 +3Application ANDA213075, ANDA207494, NDA050795 +2
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 30 tablet, delayed release in 1 bottle | 46708-484-30 | Alembic PharmaceuticalsIndia | 15 October 2022 |
| 100 tablet, delayed release in 1 bottle | 46708-484-31 | Alembic PharmaceuticalsIndia | 4 January 2022 |
| 60 tablet, delayed release in 1 bottle | 46708-484-60 | Alembic PharmaceuticalsIndia | 4 January 2022 |
| 500 tablet, delayed release in 1 bottle | 46708-484-71 | Alembic PharmaceuticalsIndia | 4 January 2022 |
| 30 tablet, delayed release in 1 bottle | 62332-484-30 | Alembic PharmaceuticalsIndia | 15 October 2022 |
| 100 tablet, delayed release in 1 bottle | 62332-484-31 | Alembic PharmaceuticalsIndia | 4 January 2022 |
| 60 tablet, delayed release in 1 bottle | 62332-484-60 | Alembic PharmaceuticalsIndia | 4 January 2022 |
| 500 tablet, delayed release in 1 bottle | 62332-484-71 | Alembic PharmaceuticalsIndia | 4 January 2022 |
| 250 tablet, delayed release in 1 bottle | 23155-611-04 | Avet PharmaceuticalsIndia | 16 March 2018 |
| 60 tablet, delayed release in 1 bottle | 23155-611-06 | Avet PharmaceuticalsIndia | 16 March 2018 |
| 60 tablet, delayed release in 1 bottle | 0591-4575-60 | Actavis Pharma | 14 August 2019 |
| 30 tablet, delayed release in 1 bottle | 68308-716-30 | Mayne Pharma Commercial | 18 December 2017 |
| 60 tablet, delayed release in 1 bottle | 68308-716-60 | Mayne Pharma Commercial | 1 February 2016 |
| 60 tablet, delayed release in 1 bottle | 43547-325-06 | Solco Healthcare | 28 November 2016 |
| 100 tablet, delayed release in 1 bottle | 43547-325-10 | Solco Healthcare | 28 November 2016 |
| 500 tablet, delayed release in 1 bottle | 43547-325-50 | Solco Healthcare | 28 November 2016 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 5 December 1967 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Doxycycline
Clinical summary
Doxycycline is a tetracycline-class drug indicated for the treatment of infections, among other approved uses. It is available as capsules, tablets and powder for injection for oral and intravenous use. MedsAcross supplies Doxycycline for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DoxycyclineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Doxycycline prescribing information (Wellhouse Pharma) · U.S. National Library of Medicine, DailyMed
Need Doxycycline 200 mg delayed-release tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.